Cladaxxa 40/10mg Tabs x 100
Flavoured and chewable tablet combining Amoxicillin and Clavulanic Acid
A flavoured and chewable tablet combining Amoxicillin and Clavulanic Acid. This product is for use in Dogs and Cats for the treatment of bacterial infections of respiratory, digestive or urinary systems and also skin or dental infections.
To be used only when clinical experience, supported where possible by sensitivity testing of the causal organism, indicates Amoxicillin / Clavulanic Acid as the drug of choice.
For the treatment of infections caused by bacteria susceptible to amoxicillin and clavulanic acid including: skin disease (including deep and superficial pyodermas); soft tissue infections (abscesses and anal sacculitis); dental infections (e.g. gingivitis); urinary tract infections; respiratory disease (involving upper and lower respiratory tract); enteritis.
Administration: for oral use.
Dosage rate and frequency: 10 mg amoxicillin and 2.5 mg clavulanic acid/kg body
weight (i.e. 12.5 mg of combined active substances per kg bodyweight), twice daily
(corresponding to 25 mg of combined active substances per kg per day).
The following table is intended as a guide to dispensing the product at the
recommended dose rate:
Bodyweight
(kg)
Number of tablets per
dose twice daily.
|
1.0-2.0 |
½ |
|
2.1-4.0 |
1 |
|
4.1-6.0 |
1 ½ |
|
6.1-8.0 |
2 |
|
>8.0 |
Use 200 mg/50 mg or 400 mg/100 mg tablet(s) |
To ensure a correct dosage body weight should be determined as accurately as possible to avoid underdosing. If the animal does not accept the tablet from hand or bowl, then the tablets may be crumbled and added to a little food and fed immediately. Duration of therapy: The majority of routine cases respond to between 5 and 7 days therapy. In chronic cases, a longer course of therapy is recommended. In such circumstances, overall treatment length must be at the clinician’s discretion but should be long enough to ensure complete resolution of the bacterial disease
List of excipients
Cellulose, microcrystalline
Magnesium stearate
Silica, colloidal anhydrous
Sodium starch glycollate (type A)
Dried autolyzed yeast
Erythrosine aluminium lake, E127
-Adverse reactions (frequency and seriousness)
Very rarely, hypersensitivity reactions to penicillins may occur in treated animals; in
these cases, administration should be discontinued and a symptomatic treatment
given.
Very rarely, gastro-intestinal disturbances (diarrhoea, vomiting, …) may occur after
administration of the product. Treatment may be discontinued depending on the
severity of the undesirable effects and a benefit/risk evaluation by the veterinary
surgeon.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
-Use during pregnancy, lactation or lay
Laboratory studies in rats and mice have not produced any evidence of teratogenic,
foetotoxic or maternotoxic effects.
The safety of the product has not been assessed in pregnant and lactating bitches
and queens.
In pregnant and lactating animals, use only according to the benefit/risk assessment
by the responsible veterinarian.
-Interaction with other medicinal products and other forms of interaction
Chloramphenicol, macrolides, sulfonamides and tetracyclines may inhibit the
antibacterial effect of penicillins because of the rapid onset of bacteriostatic action.
Penicillins may increase the effect of aminoglycosides.
-Overdose (symptoms, emergency procedures, antidotes), if necessary
Mild gastrointestinal symptoms (diarrhoea, nausea and vomiting) may occur after overdose of the product and symptomatic treatment should be initiated when necessary.